📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 placeSee list

Second judge says US not liable in Moderna COVID-19 vaccine patent case

Published 04/26/2023, 06:59 PM
Updated 04/26/2023, 08:25 PM
© Reuters. FILE PHOTO: Vial labelled "Moderna coronavirus disease (COVID-19) vaccine" placed on displayed Moderna logo is seen in this illustration picture taken March 24, 2021. REUTERS/Dado Ruvic/Illustration
PFE
-
ABUS
-
MRNA
-

By Blake Brittain

(Reuters) - Moderna (NASDAQ:MRNA) Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine.

Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit.

Connolly did not include the reasoning for his decision in his order, which he announced from the bench following arguments in the case.

A Moderna spokesperson said in a statement that the company "respectfully disagrees" with the decision and is confident that discovery will support its position. Representatives for Alnylam did not immediately respond to a request for comment.

Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc (NYSE:PFE) in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.

The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year.

Moderna said in the Alnylam case that the court should dismiss claims that were based on vaccines it sold to the U.S. government and that Alnylam should instead seek damages from the government itself. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.

Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma (NASDAQ:ABUS) Corp and Genevant Sciences GmbH.

© Reuters. FILE PHOTO: Vial labelled

U.S. District Judge Mitchell Goldberg rejected Moderna's motion in that case last year and said it had not yet proven the government was more than an "incidental beneficiary" of the shots.

Goldberg denied the motion for a second time last month after the federal government backed Moderna's position.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.